Long-Term Changes in Patient-Reported Outcome Measures in People With Multiple Sclerosis 55 Years and Older: Analysis From the New York State Multiple Sclerosis Consortium
Abstract
Background: Patient-reported outcome measures (PROMs) are increasingly utilized in observational and regulated studies of people with multiple sclerosis (MS). However, the impact of aging on PROMs for people with MS remains largely unknown. This study explores the cross-sectional characteristics and longitudinal trajectories of PROMs to determine their ability to predict clinical progression in a large group of people with MS 55 years and older.
Methods: Included in the analysis were people with MS enrolled in the New York State Multiple Sclerosis Consortium (NYSMSC), 55 years or older, with at least 3 clinical visits recorded in the consortium database. All people in the NYSMSC complete PROMs through the LIFEware questionnaire. Additional clinical measures were also collected. The percentage of people with MS who reported severe limitations within each of the LIFEware domains was compared at their baseline visit (≥ 55 years) and at the most recent follow-up visit (average follow-up of 8.3 years). Comparisons between people with MS with stable or increasing disability were also performed.
Results: Of 658 eligible people in the NYSMSC (mean age at most recent follow-up, 66.6 years), a greater percentage reported decreased ability since baseline in all physical PROMs domains (getting up from sofa, 38.4% to 48.8%, P < .001; standing for more than 30 minutes, 59.3% vs 66.9%, P < .001; and functional limitations in all extremities, P < .007). Contrarily, the group reported…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 658 participants or records.
Read the paper
Related studies
- A Coupled SYSTEM of Intracellular Ca 2+ Clocks and Surface Membrane Voltage Clocks Controls the Timekeeping Mechanism of the Heart’s Pacemaker
- A Comprehensive Review on the Therapeutic Potential of Curcuma longa Linn. in Relation to its Major Active Constituent Curcumin
- Cancer epigenetics: Moving forward
- Current developments in LC-MS for pharmaceutical analysis
- Myricetin: A comprehensive review on its biological potentials
- A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.